Biosimilar Candidate BI 695501 and Adalimumab Reference Product Have Similar Efficacy and Safety in Patients with Moderately-to-Severely Active Rheumatoid Arthritis (RA): 1-Year Results from a Phase III Study-MedSci.cn

Biosimilar Candidate BI 695501 and Adalimumab Reference Product Have Similar Efficacy and Safety in Patients with Moderately-to-Severely Active Rheumatoid Arthritis (RA): 1-Year Results from a Phase III Study

Cohen, SB; Alonso-Ruiz, A; Klimiuk, PA; Lee, E; Peter, N; Czeloth, N; Jayadeva, G

ARTHRITIS & RHEUMATOLOGY, 2017; 69 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务